Nigeria's Neimeth posts strong Q1 revenue gains but debt costs cloud the recovery

Neimeth International Pharmaceuticals, one of Nigeria's longest-established drugmakers, posted strong revenue growth in the first quarter of 2026, continuing a turnaround that has lifted the Lagos-listed group out of three years of losses — even as escalating finance costs and an entrenched debt load underscore how challenging the operating environment remains for the country's pharmaceutical industry.

The company, listed on the Nigerian Exchange and traceable to the local subsidiary of Pfizer that operated in Nigeria from the 1950s onwards, reported continued top-line momentum in the three months to 31 March 2026, building on a full-year 2025 in which revenue rose 64 per cent to N7.37bn and the group swung to a net profit of N982mn from a N885mn loss a year earlier. Operating profit in 2025 surged from a near-negligible N18.9mn to N2.7bn — an extraordinary 14,257 per cent jump — reflecting both stronger sales of the company's pharmaceutical portfolio and improved operational discipline.

The recovery owes much to Neimeth's decisive break from a high-interest debt trap that had weighed on its income statement for several years. The company restructured its outstanding obligations with major Nigerian lenders into long-term loans with tenors of up to ten years, allowing principal repayments to be spread gradually while the company maintains the working capital needed to scale operations. Even so, finance costs continue to bite. Interest expenses rose 40 per cent in 2025, and surged 198 per cent year-on-year to N1.32bn during the nine months to September 2025, with profit growth materially constrained by the burden of servicing legacy debt and managing foreign exchange exposure on dollar-denominated obligations.

The company's leadership has been candid about the trade-off. "This cost has to do with the interest we paid on debt that was carried forward from the previous year," said Valentine Okelu, the chief executive. "It would have been higher than this if not for the fact that we did everything we could to get the loan restructured… so instead of dumping heavy interest rates… we were able to get them to restructure the loans for up to 10 years."

Beyond debt restructuring, Neimeth has moved to clean up its balance sheet through a court-supervised scheme of arrangement. Shareholders approved the reorganisation at an ordered meeting on 31 March 2026, allowing the company to reduce its share premium account from N2.38bn to N390mn and transfer the N1.99bn balance into retained earnings. Subject to final regulatory and judicial approval, the move is intended to strengthen distributable reserves, absorb accumulated losses and improve financial flexibility — all without raising fresh capital from external investors.

The strategic logic behind the recovery is straightforward: a pharmaceutical company cannot finance long-cycle manufacturing, regulatory compliance and distribution infrastructure with short-term, high-interest bank debt. The mismatch between funding structure and operational needs has plagued Nigerian pharmaceutical groups for years, and is now driving a more fundamental rethink across the sector. Borrowing costs remain elevated by historical standards, and input pressures — including foreign exchange volatility and the rising cost of imported active pharmaceutical ingredients — persist. Neimeth's pivot toward what management has described as a search for "patient capital" reflects a broader industry recognition that conventional debt financing is increasingly incompatible with the sector's operational profile.

The challenges, however, remain considerable. External debt at Neimeth stood at approximately N8.6bn, dwarfing combined share capital of around N2.6bn. Despite a more than threefold increase in revenue between 2022 and 2025, the underlying capital structure remains stretched, and foreign currency obligations continue to expose the company to balance sheet volatility. The 2024 financial year, for instance, saw an FX-induced loss of N2.8bn substantially erase the benefit of capital raised in early 2023. Until the cost and structure of foreign currency debt is more meaningfully addressed, profitability is likely to remain fragile — a point Nigerian analysts have made repeatedly in commentary on the company.

The broader context for Nigerian pharmaceutical manufacturing is mixed. The country imports the overwhelming share of finished medicines and active pharmaceutical ingredients, leaving domestic producers vulnerable to currency depreciation and supply chain disruption. Successive government interventions — including import substitution policies, fiscal incentives for local manufacturing and the Central Bank of Nigeria's various forex allocation schemes — have produced uneven results. Domestic groups, including Neimeth, Fidson Healthcare and May & Baker, have continued to invest in capacity expansion, regulatory upgrades and product development, but their progress has been repeatedly checked by macroeconomic shocks.

For Neimeth specifically, the first-quarter 2026 numbers should be read as a continuation of the upward trajectory established in 2025, rather than a definitive resolution of the company's structural issues. Strong top-line growth and improving operating leverage are translating into headline profitability, and the debt restructuring has materially reduced the immediate risk of distress. But the spread between operating profit and net profit — chronically compressed by finance costs — will remain the key indicator to watch over the coming quarters. So too will the pace at which the company can convert the relief afforded by the scheme of arrangement and loan restructuring into sustained margin expansion and balance sheet repair.

Underlying all of this is a more fundamental investment question: whether a recovering but capital-constrained Nigerian pharmaceutical group can scale into a market that combines significant unmet demand with persistent macroeconomic friction. The answer matters not just for Neimeth's shareholders, but as a real-time test case for the viability of indigenous pharmaceutical manufacturing in one of Africa's largest economies — and for the readiness of patient, longer-duration capital to back it.